Galcanezumab

• Migraine Prevention
• Episodic Cluster Headache
• Chronic Migraine
• CGRP-Targeted Therapy

Galcanezumab (Emgality) is a humanized monoclonal antibody that binds and neutralizes calcitonin gene-related peptide (CGRP), a key signaling molecule in migraine and cluster headache pathophysiology. It is delivered as a once-monthly subcutaneous injection for migraine prevention and as a higher-dose monthly injection during cluster periods. For patients who have failed multiple oral preventives or who cannot tolerate them, galcanezumab and its CGRP-class peers represent the first migraine-specific preventive class designed from the ground up rather than borrowed from cardiology, neurology, or psychiatry. Approved by the FDA in 2018, galcanezumab joined an expanding therapeutic area that has dramatically improved options for the roughly 39 million Americans living with migraine — and for the much smaller but profoundly affected population with cluster headache, often described as one of the most painful human experiences.

Mechanism of Action

CGRP is a 37-amino-acid neuropeptide released from activated trigeminal sensory fibers during migraine attacks. It drives cranial vasodilation, neurogenic inflammation around dural blood vessels, sensitization of trigeminal nociceptors, and central sensitization in the trigeminocervical complex. Elevated CGRP levels have been measured in the cranial circulation of patients during migraine attacks and during cluster periods, and intravenous CGRP infusion can provoke migraine in susceptible individuals. Galcanezumab is an IgG4 monoclonal antibody that binds CGRP itself (the ligand), preventing it from engaging its receptor. This is a slightly different approach from erenumab, which blocks the CGRP receptor directly, though both classes deliver similar clinical efficacy. The other CGRP ligand antibodies — fremanezumab and eptinezumab — share galcanezumab's mechanism. Because monoclonal antibodies are large proteins (about 150 kDa) that do not cross the blood-brain barrier well, they likely act peripherally on the trigeminal ganglion, dura, and meningeal nerve endings rather than within the central nervous system. The half-life is about 27 days, which supports monthly dosing, and steady-state concentrations are reached within several months. Importantly, galcanezumab does not provide acute relief of an established attack — it is purely preventive — so patients also need separate acute therapy.

Clinical Use

Galcanezumab is FDA-approved for prevention of episodic and chronic migraine in adults and for treatment of episodic cluster headache. It is generally reserved for patients with at least four migraine days per month who have failed at least two preventive trials of adequate dose and duration — typical first-line oral agents include topiramate, propranolol, [amitriptyline] or other tricyclic antidepressants, venlafaxine, or candesartan. Compared with the small-molecule oral CGRP receptor antagonists used for prevention (atogepant, rimegepant), monoclonal antibodies offer monthly dosing and may be preferred when oral pill burden is a concern or when injection is acceptable. Other CGRP monoclonals include erenumab, fremanezumab, and eptinezumab, which differ in route, dosing interval, and binding target but produce similar migraine-day reductions of 1.5-2.5 days per month over placebo in clinical trials. Patients should still have access to acute treatment for breakthrough attacks — a triptan such as sumatriptan, the gepant ubrogepant, or lasmiditan for those with cardiovascular contraindications to triptans. The American Headache Society's 2024 consensus statement supports CGRP therapies as first-line preventive options when patient preference, comorbidities, or prior treatment failures favor them. Patients also benefit from non-pharmacologic strategies including consistent sleep, hydration, regular meals, exercise, and trigger identification — see our overview of chronic stress and physical illness.

How to Take It

Galcanezumab is given as a subcutaneous injection in the abdomen (at least two inches from the navel), thigh, upper arm (back of arm), or buttock, rotating sites with each dose to reduce injection site reactions. For migraine prevention, the regimen is a 240 mg loading dose (two 120 mg injections back-to-back at separate sites) on day one, followed by 120 mg once monthly. For episodic cluster headache, the dose is 300 mg (three 100 mg injections, or in available presentations following the prescribing information) at the onset of the cluster period, repeated monthly until the cluster period ends. Store the prefilled pen or syringe in the refrigerator (36-46 F); bring it to room temperature for 30 minutes before injecting to reduce sting, but do not warm it artificially with hot water or microwave. Inspect the solution — it should be clear and colorless to slightly yellow; do not use if cloudy or particulate. After injection, dispose of the device in a sharps container. If a dose is missed, give it as soon as possible and resume monthly dosing from that date — there is no need to double the next dose. Improvement in migraine days is typically seen within the first month for responders, with maximum benefit by month three; some patients are slow responders and benefit becomes apparent only by month six.

Monitoring and Follow-Up

A headache diary documenting monthly migraine days, headache intensity, acute medication use, sleep, and disability scores (such as the MIDAS or HIT-6 questionnaires) is the most important monitoring tool. A meaningful response is usually defined as a 50% or greater reduction in monthly migraine days at three months; a 30-50% reduction may still warrant continuation if quality of life is improved. If no response by three to six months, switching to a different CGRP agent (receptor antagonist if galcanezumab failed, or vice versa) is reasonable, as cross-class response is unpredictable. Routine lab monitoring is not required, though baseline blood pressure should be checked because CGRP plays a role in vascular tone and cases of new or worsening hypertension have been reported with the receptor antagonist erenumab and, more rarely, with the ligand antibodies. Constipation is common, particularly with erenumab but also with galcanezumab; manage proactively with hydration, fiber, daily walking, and stool softeners as needed. Most insurance plans require periodic reauthorization based on documented benefit and continued migraine frequency above a defined threshold.

Special Populations

No dose adjustment is needed for renal or hepatic impairment, and the elderly tolerate galcanezumab without dose change. Pregnancy registry data are limited; because IgG antibodies cross the placenta in increasing amounts during the second and third trimesters, most clinicians stop CGRP therapy when pregnancy is being attempted or confirmed and resume after delivery if needed. Women planning pregnancy should discuss timing well in advance because the long half-life means residual drug remains for months after the last injection. Lactation transfer is likely minimal because IgG antibodies are large and poorly absorbed from the infant gut, but data are limited. Pediatric efficacy and safety data are still emerging, with pediatric trials ongoing or recently completed. Patients with cardiovascular disease may use galcanezumab — unlike triptans it does not cause vasoconstriction — but baseline blood pressure should be optimized.

When to Contact Your Doctor

Seek emergency care for hives, throat tightness, facial swelling, wheezing, or dizziness after an injection — anaphylaxis and serious hypersensitivity reactions have been reported and can occur even after multiple uneventful doses. Call the office for severe constipation unresolved with standard measures, persistent injection-site reactions (redness, swelling, or pain lasting more than several days), new uncontrolled hypertension, worsening headache pattern despite adherence, or any symptoms suggesting a different headache disorder developing on top of migraine.

Insurance coverage for CGRP monoclonal antibodies has become more straightforward than at launch but typically still requires prior authorization documentation of failed oral preventives and minimum migraine frequency. Patient assistance programs and manufacturer copay savings cards can reduce out-of-pocket costs substantially for those with commercial insurance, while Medicare patients may have higher cost-sharing depending on plan design. Patients should also be aware that migraine frequently coexists with sleep disturbance, anxiety, depression, and TMJ-related muscle pain — see our discussion of chronic stress and physical illness and how stress affects your body for context. Lifestyle pillars (consistent sleep schedule, regular meals, hydration, aerobic exercise, limiting caffeine fluctuations, and trigger journaling) magnify the benefit of any preventive medication and remain part of every treatment plan. Many patients on CGRP therapy gradually need fewer acute treatments, but it is rarely appropriate to discontinue acute therapy entirely.

If migraines are interfering with your work, sleep, or quality of life and you would like to discuss whether a CGRP-targeted preventive is right for you, contact us or schedule a visit at Zimmer Medical Group for a structured headache evaluation and treatment plan.